A combination of optogenetic gene therapy and use of a light stimulation medical device for the treatment of retinitis pigmentosa was well tolerated among the first cohort of patients enrolled in the PIONEER study, according to data reported at the Association for Research in Vision and Ophthalmology annual meeting.
According to the abstract, there are more than 100 known mutations of retinitis pigmentosa (RP).
“It’s a unique trial and a unique approach for vision restoration that is independent of the underlying gene defect,” Joseph N. Martel, MD, assistant professor of
Uncategorized